MedTrace Logo

Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis

NCT05378646 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-05-18

No results posted yet for this study

Summary

The primary purposes of the study are to evaluate the effectiveness of Ingaron in the complex therapy of chronic prostatitis, to assess the safety of using Ingaron in patients with chronic prostatitis.

Conditions

  • Chronic Prostatitis

Interventions

DRUG

Interferon gamma human recombinant (IFN-G)

received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein

Sponsors & Collaborators

  • SPP Pharmaclon Ltd.

    lead INDUSTRY

Principal Investigators

  • Leonid Apanansky, Master · SPP Pharmaclon Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-29
Primary Completion
2009-12-31
Completion
2010-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05378646 on ClinicalTrials.gov